CCM
TBPH icon

Consonance Capital Management’s Theravance Biopharma TBPH Stock Holding History

Consonance Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-731,909
Closed -$23.9M – 27
2018
Q3 		$23.9M Buy
+731,909
New +$19.9M 1.29% 25

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Consonance Capital Management's TBPH Position: Q4 2018 in Review

Consonance Capital Management sold out of Theravance Biopharma (TBPH) in Q4 2018, closing a stake of 731,909 shares — an estimated $23.9M sold.

Consonance Capital Management first reported a position in TBPH in Q3 2018 and held it in 1 quarter. The position peaked at $23.9M in Q3 2018. 96 funds tracked by Wall St. Rank hold TBPH as of Q4 2018.

  • Consonance Capital Management reported no remaining Theravance Biopharma position as of Q4 2018 after selling out during the quarter.
  • Consonance Capital Management sold 731,909 Theravance Biopharma shares in Q4 2018, an estimated $23.9M.
  • Consonance Capital Management first reported a position in Theravance Biopharma in Q3 2018 and held it in 1 quarter.
  • Consonance Capital Management's Theravance Biopharma position peaked at $23.9M in Q3 2018.
  • 96 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2018.

Based on Consonance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.